NCT04782661

A Study of JNJ-70075200 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-70075200 in Healthy Participants

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate safety and tolerability of JNJ-70075200 compared with placebo after administration of single ascending doses of JNJ-70075200 as oral solution (Part 1); multiple ascending doses of JNJ-70075200, administered as oral solution over 14 consecutive days (Part 2); and the option of a single dose of JNJ-70075200 administered as an oral solid formulation (Part 3).

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-70075200	JNJ-70075200 solution or solid formulations will be administered orally.
DRUG	Placebo	Placebo solution will be administered orally.

Timeline

• Start date: 2022-03-01
• Primary completion: 2022-05-09
• Completion: 2022-09-23
• First posted: 2021-03-04
• Last updated: 2022-01-05

Locations

1 site across 1 country: Netherlands